Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Cash from Investing Activities (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed Cash from Investing Activities for 8 consecutive years, with -$4000.0 as the latest value for Q3 2022.

  • Quarterly Cash from Investing Activities rose 69.23% to -$4000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was -$135000.0 through Dec 2022, up 81.07% year-over-year, with the annual reading at -$29000.0 for FY2022, 95.93% up from the prior year.
  • Cash from Investing Activities hit -$4000.0 in Q3 2022 for Aptevo Therapeutics, up from -$118000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $63.8 million in Q3 2018 to a low of -$391000.0 in Q2 2021.
  • Historically, Cash from Investing Activities has averaged $12.9 million across 5 years, with a median of -$8500.0 in 2021.
  • Biggest five-year swings in Cash from Investing Activities: skyrocketed 18479.08% in 2020 and later crashed 100.68% in 2021.
  • Year by year, Cash from Investing Activities stood at $63.8 million in 2018, then crashed by 93.33% to $4.2 million in 2019, then tumbled by 102.07% to -$88000.0 in 2020, then plummeted by 34.09% to -$118000.0 in 2021, then soared by 96.61% to -$4000.0 in 2022.
  • Business Quant data shows Cash from Investing Activities for APVO at -$4000.0 in Q3 2022, -$118000.0 in Q4 2021, and -$13000.0 in Q3 2021.